Vernalis PLC - Results Announcement for the year ended 30 June 2017

Vernalis plc (LSE: VER) today announces its audited financial results for the year ended 30 June 2017, following the year-end trading update published on 18 July 2017.

US Commercial performance:

  • Tuzistra® XR prescriptions increased three-fold to approximately 35,000 for the year (2016: 12,000), reflecting:
  • increased insurance coverage and pharmacy stocking
  • improved salesforce effectiveness following expansion to 100 representatives, now brought in-house
  • refined marketing messaging and physician targeting
  • improved patient affordability following enhancements in Vernalis’ patient assistance program
  • Potential of Tuzistra® XR remains significant and has been seen across the US, with high performing sales representatives in all targeted regions 

For more information please see the full press release below


More within